June 06, 2026
7 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3 trials. During a symposium at the American Diabetes Association Scientific Sessions, researchers presented data from phase 3 trials investigating retatrutide (Eli Lilly), a once-weekly
2,274 words~10 min read
